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Alessandra Saldanha de Mattos Matheus* and Marília Brito GomesAbstract
Background: Type 1 diabetes (T1DM) is considered to be one of the most significant risk factors for the
development of coronary artery disease (CAD). However, the specific risk predictor models for T1DM are subject
to many limitations.
Case presentation: We report the case of a 42-year-old Caucasian woman presenting with T1DM for 26 years.
During her chronic hyperglycemic evolution (mean of HbA1c > 3 percentage points above the superior limit)
without microvascular complications, this patient presented with early and aggressive coronary artery disease,
despite the lack of classical risk factors for CAD
Conclusions: The rapidly progressive macrovascular disease observed in this case demonstrates the different
degrees of aggressiveness and unpredictable clinical evolution observed in some cases. It also confirms the need
for a multi-factorial, early and optimized clinical management regime.
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Cardiovascular diseases are the main cause of morbidity
and mortality among both type 1 and type 2 diabetes
(DM) patients, affecting almost half of all diabetics. Its
total prevalence has been estimated at about 55% of dia-
betic patients, as compared to 2-4% of the total popula-
tion [1].
Type 1 diabetes (T1DM) is considered one of the most
significant risk factors for the development of coronary
artery diseases (CAD). However, it should be noted that,
to date, the specific risk predictor models for T1DM are
subject to many limitations [2]. The risk of CAD is
expected to increase between two and four times [3],
and DM is the third most important risk factor for this
disease pathogenesis [4]. Consequently, diabetes also in-
creases the risk of acute coronary syndromes (ACS), the
incidence of which reaches the level of 20% within
7 years, as compared to an incidence of 3.5% among
non-diabetics – an increase in incidence similar to indi-
viduals who had previously suffered an acute myocardial* Correspondence: alessandramatheus79@yahoo.com
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distribution, and reproduction in any mediuminfarction (AMI) [3]. In Brazil, fasting glucose above
126 mg/dL corresponds to a three-fold increase in the
risk for AMI [5]. It is also important to identify any of
the well-determined specific risk factors for T1DM, such
as nephropathy and autonomic neuropathy, as well as
further subclinical atherosclerosis, which may already be
affecting these patients at a late stage of disease progres-
sion [6]. When compared to non-diabetics, T1DM pa-
tients show more extensive lesions, a reduced ejection
fraction of the left ventricle (LV), more cardiac events
and a higher frequency of silent ischemia. They still
present impairment of microcirculation and endothelial
dysfunction that contributes to tissue perfusion disturb-
ance [1,5]. Another intriguing fact is that T1DM reduces
the differences between genders with respect to coronary
calcification, with more significant effects on calcifica-
tion seen in women relative to men [7].
The present case report describes the case of a female
type 1 diabetic with extensive, rapidly progressive
macrovascular disease that is not associated with clas-
sical risk factors for CAD.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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This case study describes a 48-year-old female patient
who was diagnosed with T1DM at the age of 16. The pa-
tient remained under regular follow-up while conducting
a labile glycemic control by first using insulin NPH twice
a day and, subsequently, using a long- acting human in-
sulin analog (from 1999 to present) [Figure 1].
There was no family history related to DM, systemic
arterial hypertension or CAD. Smoking habits were ab-
sent during all her life. Her father died from stroke after
the age of 70 years and her mother died from acute
myocardial infarction when she was 75 years. Lipid pro-
file and body mass index (BMI) and Blood pressure
levels were normal, as were acute phase markers (C-re-
active protein – CRP, homocysteine, apoprotein A and
apoprotein B) [Figures 2, 3 and 4]. Accordingly, this pa-
tient had a low risk for CAD. Proteinuria levels were
within normality until the age of 40 years and after this
urinary albuminuria excretion rate (UAER) was either
within normality [Figure 5].
At the age of 42 (26 years of disease evolution), she
presented for the first time with clinical symptoms of
acute coronary syndrome (ACS) with an acute myocardial
infarction (AMI). The cineangiocoronarography (CAT) of
the left coronary artery disclosed extended stenosis of 90%
at the anterior descending artery (DA) after the first
diagonal branch and 80% at the proximal segment of the
diagonal artery. The right coronary artery presented an ex-
tended stenosis of 90% before its bifurcation, and its pos-
terior branches showed a stenosis of 90% at the medium
segment [Figures 6 and 7]. She was submitted to a myo-
cardial revascularization by implanting an internal left
mammary graft for DA, an internal right mammary graft
for the diagonal artery, and an aorta coronary bypass for
the marginal coronary artery. At the age of 44 (2 years
after the first ACS event), she presented another AMI, this
time involving the right coronary artery (RCA) in the
proximal portion with obstruction of 80-90% [Figure 8].
Stents with rapamycin were immediately implanted at theFigure 1 Glycemic control during the follow up.right coronary artery. By this time, the echocardiogram
disclosed no diastolic dysfunction, showing an ejection
fraction of 70%.
At the age of 48, her last evaluation disclosed a pre-
dominantly systolic hypertension, and her myocardial
scintigraphy showed an ischemia induced by effort, des-
pite the optimized cardiovascular therapy.
Discussion
This case report described a T1DM patient who did not
present nephropathy, retinopathy or classical risk factors
for CAD. However, during her chronic hyperglycemic
evolution due to extremely difficult control (mean of
HbA1c > 3 percentage points above the upper limit), she
presented with early and aggressive coronary artery
disease.
From a clinical point of view, it is well known that
DM increases cardiovascular risk. During the last de-
cades, several epidemiological studies demonstrated that
some risk factors, including systemic arterial hyperten-
sion, diabetes, smoking, dyslipidemia [8], family history,
sedentary lifestyle, central obesity and poor ingestion of
fruits and vegetables, account for almost 90% of cases of
CAD in the global population [4]. Nevertheless, while
the precise reasons for this increase in risk remain un-
clear, kidney disease and the usual risk factors for CAD
seem to contribute.
At present, the role of glycemic control as a contributive
factor for CAD is still controversial. In recent decades, sev-
eral clinical trials have investigated the effect of intensive
treatment of hyperglycemia on cardiovascular risk reduc-
tion in T1D [9]. Although the complete role of hypergly-
cemia in the pathogenesis of cardiovascular diseases (CD)
is still speculative, relevant studies, such as the The
Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications (DCCT/
EDIC) Study, have shown advantages to glycemic control
through intensified insulin treatment for a reduction in
macrovascular events. After a 17-year follow-up, it was
Figure 2 Lipid profile. Note that prior to coronary event at 42 years-old, she had a normal lipid profile.
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of any CD in 42% of patients and of non-lethal myocardial
infarction and cerebrovascular accident in 57% of patients.
This reduction in risk was mostly associated with the re-
duction in glycohemoglobin during DCCT [9].
The Pittsburgh Epidemiology of Diabetes Complications
Study (EDC) found no significant relationship between
fasting plasma glucose or exposure time to glucose and
the incidence of CAD [10,11]. Another important study,
the EURODIAB [12], corroborated the relevant predictor
role of albuminuria in the pathogenesis of CAD in T1DM.
It also verified a stronger link between macroangiopathy
and metabolic syndrome markers than with hypergly-
cemia itself. Moreover, gender-specific risk for SAP
(systolic arterial pressure), triglycerides (or HDL choles-
terol), and the waist-to-hip ratio were associated with the
progression of CAD. [12] The main lesson learned from
these results is that intensive and early treatment of hyper-
glycemia in patients with short duration of diabetes and
low cardiovascular risk leads to cardiovascular benefits.
Besides the classical risk factors and hyperglycemia, it is
important to identify the specific risk predictors for CAD
in T1DM. Nephropathy is a more significant risk pre-
dictor, which has already been recognized, confirmed and
has long been associated with an overall increased mortal-
ity risk, particularly due to cardiovascular disease [13].Figure 3 BMI during follow up.Besides reflecting the increase in insulin resistance, pos-
sibly the culprit in the pathogenesis of CAD in T1D,
microalbuminuria is also a marker of impairment of renal
function in its early stages as stated by Steno Investigators
[14]. The endothelial dysfunction that usually precedes
microalbuminuria [15] is probably the link between the
development of renal and cardiovascular complications
commonly seen in T1D. .Another complication usually in-
volved in the risk for CAD is the cardiovascular auto-
nomic neuropathy. In patients with long-term T1DM, the
response of myocardial blood flow to sympathetic stimula-
tion appears to be jeopardized inside the myocardial areas
with autonomic denervation, indicating a defective vaso-
dilator response of the coronary vessels. There are several
mechanisms that may contribute to early death from
CAD in these patients with autonomic neuropathy, in-
cluding abnormalities in coronary vasomotor capacity,
arrhythmia and changes in systolic and diastolic function,
as the threshold is lower at the setting of a relative
increase in sympathetic tone. Such situations are com-
monly seen in diabetic individuals with sympathovagal im-
balance [6].
However, it is worth noting that there are many limita-
tions to the existing risk predictor models. While some
tools are available for the evaluation of risk of cardiovas-
cular events in the population in general and for T2DM,
Figure 4 Blood pressure levels during follow up.
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T1DM. These models do not take into account a lower
age range, nor do they consider several co-morbidities
specifically related to DM. Therefore, they are likely to
provide mistaken risk estimation for patients, including
some that are high risk. Consequently, there is an obvi-
ous need for creating new specific risk predictor models
for T1DM that encompass all of these factors [2].
The predisposition to unstable plaques in DM results
from the abnormal metabolic conditions shown by these
patients, which lead to alterations in endothelial, inflam-
matory and smooth muscle cells [16]. In addition, there is
a strong tendency toward thrombosis due to functional al-
terations in platelets and within the coagulation cascade
[17]. The metabolic abnormalities that characterize dia-
betes, such as hyperglycemia, increased free fatty acids
and insulin resistance, trigger molecular mechanisms that
contribute to vascular dysfunction and, consequently, to
the increase in cardiovascular risk among T1DM patients
[18,19] through both microvascular and macrovascular
complications [20,21].Figure 5 UAER levels during follow up.Genetics can also be important. Haptoglobin is consid-
ered as another antioxidant defense in diabetes, because
this plasma protein binds free hemoglobin resulting in the
inhibition of iron-induced oxidative damage. T1D patients
with haptoglobin genotype 2-2, which determines lower
antioxidant capacity, presented higher incidence of CAD
after a follow-up of 18 years when compared to those with
genotype 1-1 [22]. Moreover, the haptoglobin genotype 2-2
was found to confer a 2-fold increased risk of cardiovascu-
lar events (myocardial infarction, stroke and death), when
compared to genotypes 1-1 and 2-1 in a recent meta
analysis [23]. Furthermore, HLA class II genes that are
expressed on infiltrated inflammatory cells and smooth-
muscle cells in atherosclerotic plaques are independently
associated with cardiovascular events and death in a
Finnish T1D study.[24].
Gender is another relevant factor. Studies demonstrate
that the impact produced by diabetes is higher amongFigure 6 The cineangiocornariography of the first acute
myocardial infarction. The left coronary artery disclosed extended
stenosis of 90% at the Anterior Descending Artery (DA) after the first
diagonal branch, and of 80% at the proximal segment of the
diagonal artery.
Figure 7 The cineangiocornariography of the first acute
myocardial infarction. The right coronary artery presented an
extended stenosis of 90% before its bifurcation and its posterior
branches showed a stenosis of 90% at the medium segment. PDA:
Posterior descending artery. RCA: right coronary artery.
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ferences is still a matter of debate [25]. In an English co-
hort with more than 23.000 T1DM patients, CAD was
responsible for 8% of deaths among men and 11% of
deaths among women under 40 years old [26]. This
study and other data also demonstrate the impact of
T1DM on the mortality of young individuals [27], specif-
ically female patients. The detection of CAD among
women is crucial because 40% of all coronary events af-
fecting female patients lead to death [28]. In addition,
67% of the sudden deaths of coronary origin are verified
in women who presented no prior manifestation [29].
On the other hand, only 50% of those presenting sug-
gestive symptoms of angina showed significant obstruct-
ive lesions after coronary angiography [30]. These data
illustrate the fact that, among the female population, theFigure 8 The cineangiocornariography of the second acute
myocardial infarction. The Right Coronary Artery (RCA) in the
proximal portion with obstruction of 80-90%.diagnosis of CAD may be a great challenge. Interestingly,
the influence of risk factors such as smoking, obesity
and particularly diabetes is considerably higher among
women than among men [31,32]. In addition, their post-
AMI prognosis is also worse compared to males, with a
higher mortality in the first year, reaching 38% among
women in comparison with 25% among men [33]. An
explanation of these phenomena may be that T1DM in-
creases the prevalence and the severity of coronary calci-
fication in women. The differences in gender associated
with fat deposition and distribution of HDL and LDL
cholesterol could explain why diabetes increases the cor-
onary calcification and the frequency of CAD in women
to a higher degree than in men [7].
Conclusions
The rapidly progressive macrovascular disease observed
in this case report, which focused a young type 1 dia-
betic patient without prior cardiovascular diseases, re-
flects the multiple phenotypes of diabetes, with different
degrees of aggressiveness and unpredictable clinical evo-
lution in some cases. Because diabetes undoubtedly leads
to a higher risk of CD and a worse long-term prognosis,
this case also confirms the need for multi-factorial, early
and optimized clinical management through glycemic,
pressure and lipid control, as well as the investigation
and control of the specific co-morbidities.
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